GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.904
EU - Europa 4.203
AS - Asia 2.618
SA - Sud America 326
AF - Africa 70
OC - Oceania 52
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.174
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.838
RU - Federazione Russa 1.494
PL - Polonia 996
SG - Singapore 739
CN - Cina 596
HK - Hong Kong 443
IE - Irlanda 361
IT - Italia 325
SE - Svezia 314
VN - Vietnam 302
BR - Brasile 259
KR - Corea 195
FI - Finlandia 189
DE - Germania 157
FR - Francia 119
GB - Regno Unito 87
IN - India 82
JP - Giappone 52
AU - Australia 51
UA - Ucraina 47
TR - Turchia 42
CA - Canada 40
ID - Indonesia 39
JO - Giordania 30
AR - Argentina 29
CI - Costa d'Avorio 26
NL - Olanda 22
ES - Italia 21
BD - Bangladesh 19
MX - Messico 18
BE - Belgio 16
EC - Ecuador 16
IQ - Iraq 16
ZA - Sudafrica 13
PK - Pakistan 10
CO - Colombia 9
MA - Marocco 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
CZ - Repubblica Ceca 8
RO - Romania 8
EG - Egitto 6
SA - Arabia Saudita 6
LT - Lituania 5
PH - Filippine 5
AZ - Azerbaigian 4
HN - Honduras 4
NG - Nigeria 4
PY - Paraguay 4
TN - Tunisia 4
VE - Venezuela 4
DK - Danimarca 3
KE - Kenya 3
MT - Malta 3
PE - Perù 3
UZ - Uzbekistan 3
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MM - Myanmar 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TW - Taiwan 2
AT - Austria 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
IL - Israele 1
JM - Giamaica 1
LK - Sri Lanka 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 14.174
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.668
Warsaw 991
Ashburn 757
Fairfield 548
Singapore 522
Dublin 361
Hong Kong 361
San Jose 351
Chandler 295
Woodbridge 264
Seattle 229
Cambridge 227
Beijing 223
Wilmington 218
Houston 197
Seoul 192
Ann Arbor 146
The Dalles 120
Altamura 105
Buffalo 102
Lawrence 95
Princeton 94
Ho Chi Minh City 89
Helsinki 87
Florence 85
Lauterbourg 78
Los Angeles 74
Jacksonville 73
Council Bluffs 60
Hanoi 57
Boston 56
Bremen 52
Munich 52
Boardman 50
Medford 50
Mumbai 50
Dallas 47
Hefei 47
New York 47
Tokyo 47
Melbourne 45
Shanghai 40
Moscow 35
San Diego 34
Dong Ket 32
Falls Church 31
Turku 29
Izmir 28
Jakarta 28
Abidjan 26
São Paulo 24
Paris 21
London 19
Norwalk 19
Clifton 16
Brussels 15
Redondo Beach 14
Washington 14
Andover 11
Guangzhou 10
Montreal 10
Orem 10
Rome 10
Barcelona 9
Brooklyn 9
Da Nang 9
Frankfurt am Main 9
Kent 9
Phoenix 9
Toronto 9
Atlanta 8
Bern 8
Chicago 8
Guayaquil 8
Hải Dương 8
Haiphong 7
Hillsboro 7
Nanjing 7
Salerno 7
Stockholm 7
Amsterdam 6
Baghdad 6
Curitiba 6
Istanbul 6
Johannesburg 6
Madrid 6
Manchester 6
Old Bridge 6
Quito 6
Rio de Janeiro 6
Aachen 5
Amman 5
Auburn Hills 5
Barnet 5
Brasília 5
Brno 5
Chennai 5
Pisa 5
Thái Bình 5
Abuja 4
Totale 9.935
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus infection in the immunocompromised host: a complex scenario with variable clinical impact 323
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 315
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. 299
HCV and lymphoproliferation 272
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. 262
Notch4 and mhc class II polymorphisms are associated with hcv-related benign and malignant lymphoproliferative diseases 255
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 253
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 244
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 240
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 225
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 224
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 222
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 222
Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation 219
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 219
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 219
Association Between Persistent Lymphatic Infection By Hepatitis C Virus After Antiviral Treatment And Mixed Cryoglobulinemia 207
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. 203
Host genetic determinants in HCV-related mixed cryoglobulinemia 198
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 197
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 195
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 191
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 190
Host genetic determinants in HCV-related mixed cryoglobulinemia 190
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 189
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 187
A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders 185
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 179
CD81 Modulation by Immobilized Monoclonal Antibodies is Able to Promote B-cell proliferation and C-MYC expression 174
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 172
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 172
Different metabolic fingerprints between HCV and HBV patients: a possible interference of the two major hepatitis viruses in basal metabolism pathways. 170
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. 170
HCV-related mixed cryoglobulinemia and BAFF promoter polymorphism 168
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 168
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 167
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 167
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 163
Host genetic determinants in HCV-related mixed cryoglobulinemia 161
ETIOLOGICAL THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME: THE ROLE OF IL28B GENOTYPE AS PREDICTOR OF RESPONSE 159
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1. 156
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 155
Alterazioni del sistema pPAF-AH/PAF in pazienti con infezione cronica da HCV 155
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 153
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. 151
Crioglobulinemia e linfoma in corso di infezione da HCV 150
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. 149
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 149
HCV-related rheumatic manifestations and therapeutic strategies 148
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 147
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 146
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 145
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 143
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 141
Efficacia del trattamento antivirale nell’indurre la regressione di cloni B cellulari alberganti la traslocazione t(14;18) nell’infezione cronica da virus C dell’epatite (HCV). 139
Hepatitis C virus infection, malignancy and liver transplantation 138
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 138
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 138
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 133
Effects of depletion of B cell by anti-CD20 monoclonal antibody in HCV+ mixed cryoglobulinemia (MC) and liver cirrhosis 133
VALUE OF IL28B GENOTYPING IN PATIENTS WITH HCV-RELATED MIXED CRYOGLOBULINEMIA: RESULTS OF A LARGE, PROSPECTIVE STUDY 133
HCV infection and carotid atherosclerosis: evidence in favour of a local viral action inside the plaque 132
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 132
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response. 131
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 130
Comportamento dell'infezione da HCV in pazienti trapiantati per HCC complicante una cirrosi HCV-correlata 130
HCV AND lymphoma: Genetic and epigenetic factors 127
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection. 127
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 125
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label cohort study. 122
The Hepatitis C Virus Infection as a Systemic Disease 121
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 120
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 119
Extrahepatic manifestations of chronic hepatitis C virus infection. 118
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 118
Hepatitis C virus lymphotrophism: lesson from a decade of studies 114
IL28B polymorphism as predictor of response to anti-HCV terapy in HCV-related mixed cryoglobulinemia syndrome 114
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. 112
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 111
Prevalenza della ricombinazione Bcl-2 in pazienti con crioglobulinemia mista HCV correlata complicata o meno da linfoma.. 91
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 89
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma. 88
Prevalence of bcl-2 recombination in hepatitis C virus related mixed cryoglobulinemia with or without complicating B-cell lymphoma 85
Modifications of Plasma PAF-AH activity in Patients with Chronic HCV infection 85
Prevalence of bcl-2 recombination in hepatitis C virus-related mixed cryoglobulinemia with or without complicating B-cell lymphoma. 82
Il riarrangiamento del bcl-2: un nuovo evento oncogenetico nei linfomi malt di soggetti HCV infetti 71
null 48
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 11
Totale 14.228
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.912
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.912
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021108 0 0 0 0 0 0 0 0 0 0 51 57
2021/2022665 10 73 30 31 40 42 17 43 30 32 99 218
2022/20231.573 142 259 93 122 122 295 214 79 172 8 41 26
2023/2024542 23 74 97 26 28 105 8 109 11 28 14 19
2024/20254.281 141 426 254 611 1.353 673 47 239 170 91 152 124
2025/20263.728 525 526 265 315 429 176 482 194 465 300 51 0
Totale 14.228